iSpecimen shares jump 10.2% premarket after approving reverse stock split, share increase, and financing amendments.

iSpecimen (ISPC) surged 10.20% in premarket trading following the announcement that its stockholder meeting on October 30, 2025, successfully approved a reverse stock split, an increase in authorized shares, and amendments to private financing and convertible securities. These measures aim to enhance financial flexibility and ensure compliance with Nasdaq requirements, signaling improved corporate governance and potential investor confidence. The move addresses structural challenges, potentially unlocking liquidity and supporting long-term operational stability. While the stock remains technically bearish with a "Strong Sell" rating, the immediate premarket rally reflects positive sentiment toward the company’s strategic restructuring.